In today’s recent session, 0.52 million shares of the Avidity Biosciences Inc (NASDAQ:RNA) have been traded, and its beta is 0.88. Most recently the company’s share price was $40.58, and it changed around $0.92 or 2.33% from the last close, which brings the market valuation of the company to $3.88B. RNA at last check was trading at a discount to its 52-week high of $42.00, offering almost -3.5% off that amount. The share price’s 52-week low was $4.82, which indicates that the recent value has risen by an impressive 88.12% since then. We note from Avidity Biosciences Inc’s average daily trading volume that its 3-month average coming to 1.35 million.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Instantly RNA has been showing a green trend so far today with a performance of 2.33% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently up 348.42% year-to-date, but still up 2.48% over the last five days. On the other hand, Avidity Biosciences Inc (NASDAQ:RNA) is 47.73% up in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $50, which translates to bulls needing to increase their stock price by 18.84% from its current value. Analyst projections state that RNA is forecast to be at a low of $50 and a high of $50.
Avidity Biosciences Inc (RNA) estimates and forecasts
Avidity Biosciences Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 346.94 percent over the past six months and at a -8.25% annual growth rate that is well below the industry average of 15.60%. The year-over-year growth rate is expected to be 35.30%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 2.64M in revenue for the current quarter. 8 analysts expect Avidity Biosciences Inc to make 4.51M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.14M and 1.84M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 23.40%. Forecasts for the next quarter put sales growth at 145.10%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -57.60%.
RNA Dividends
Avidity Biosciences Inc’s next quarterly earnings report is expected to be released in July.
